Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
Open Access
- 5 November 2022
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 12 (1) , 145-159
Abstract
Introduction Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacologically active metabolite as dimethyl fumarate (DMF) and similar efficacy and safety profiles, but with demonstrated fewer gastrointestinal (GI) related adverse events (AEs). There are limited data characterizing persistence and adherence to DRF in the real world. Methods This retrospective analysis of the AcariaHealth Specialty Pharmacy Program included patients with MS initiating DRF from 1 December 2019 to 30 January 2021. This analysis evaluated persistence, measured as proportion of patients remaining on therapy; discontinuation rate due to GI AEs; and adherence measured by proportion of days covered (PDC). Results Overall, 1143 patients were included; 433 (37.9%) patients had been treated with prior DMF and switched to DRF. Persistence was high in both groups: the estimated proportion of patients remaining on DRF at 16 months was 82.3% [95% confidence internal (CI) 77.2–86.3%], and 90.1% (95% CI 82.2–94.6%) in the DMF to DRF group. Fifty-two (4.5%) patients overall and 15 (3.5%) in the DMF switch subgroup discontinued DRF due to GI AEs. Mean PDC was 90.8% (95% CI 89.2–92.5%), and 85.4% (95% CI 83.3–87.4%) of patients achieved PDC ≥ 80% in the overall population. In the DMF to DRF group, mean PDC was 90.7% (95% CI 88.0–93.5%), and 84.8% (95% CI 81.4–88.1%) of patients achieved PDC ≥ 80%. Conclusion In this analysis of > 1000 patients treated with DRF in real-world clinical practice, overall persistence at 16 months was high, treatment discontinuation due to GI AEs was low, and patients were highly adherent to therapy. Of 433 patients who switched from DMF to DRF, most (> 90%) were able to tolerate and persist on DRF after switching. Graphical abstract available for this article. Graphical AbstractKeywords
Funding Information
- Biogen
This publication has 37 references indexed in Scilit:
- Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2Proceedings of the National Academy of Sciences, 2016
- Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherenceRespiratory Medicine, 2016
- Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl FumarateInternational Journal of MS Care, 2015
- Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNSActa Neuropathologica, 2015
- Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literaturePatient Preference and Adherence, 2014
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAEJournal of Clinical Investigation, 2014
- Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple SclerosisJournal of Managed Care Pharmacy, 2013
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple SclerosisNew England Journal of Medicine, 2012
- Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdvances in Therapy, 2010
- Good and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurrent Medical Research and Opinion, 2009